PMID- 36120448
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20220924
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver 
      disease?
PG  - 984041
LID - 10.3389/fendo.2022.984041 [doi]
LID - 984041
AB  - Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease 
      and affects a considerable proportion of the general population worldwide. 
      Obesity is a major risk factor for development and progression of NAFLD and 
      weight loss is an effective intervention for the management of NAFLD. However, 
      few patients achieve substantial and sustained weight loss with lifestyle 
      measures. Therefore, antiobesity agents are frequently considered in patients 
      with NAFLD but there are limited data on their safety and efficacy. In the 
      present review, we discuss the role of antiobesity agents in the management of 
      NAFLD. All approved antiobesity agents appear to reduce transaminase levels and 
      to improve steatosis in patients with NAFLD. However, their effects on fibrosis 
      are less well studied and whether they affect liver-related outcomes, including 
      progression to cirrhosis and hepatocellular cancer, is unknown. The glucagon-like 
      peptide-1 receptor agonists, liraglutide and semaglutide, appear to represent a 
      first-line option in obese patients with NAFLD and type 2 diabetes mellitus 
      (T2DM) since they induce considerable weight loss and have been extensively 
      studied in patients with T2DM. However, more studies are needed to evaluated 
      their effects on liver-related and cardiovascular outcomes in patients with 
      NAFLD, particularly in those without T2DM.
CI  - Copyright (c) 2022 Tsankof, Neokosmidis, Koureta, Veneti, Cholongitas and 
      Tziomalos.
FAU - Tsankof, Alexandra
AU  - Tsankof A
AD  - First Propedeutic Department of Internal Medicine, First Department of Internal 
      Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 
      Thessaloniki, Greece.
FAU - Neokosmidis, Georgios
AU  - Neokosmidis G
AD  - First Propedeutic Department of Internal Medicine, First Department of Internal 
      Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 
      Thessaloniki, Greece.
FAU - Koureta, Evgenia
AU  - Koureta E
AD  - Laiko General Hospital, Medical School, National and Kapodistrian University of 
      Athens, Athens, Greece.
FAU - Veneti, Stavroula
AU  - Veneti S
AD  - First Propedeutic Department of Internal Medicine, First Department of Internal 
      Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 
      Thessaloniki, Greece.
FAU - Cholongitas, Evangelos
AU  - Cholongitas E
AD  - Laiko General Hospital, Medical School, National and Kapodistrian University of 
      Athens, Athens, Greece.
FAU - Tziomalos, Konstantinos
AU  - Tziomalos K
AD  - First Propedeutic Department of Internal Medicine, First Department of Internal 
      Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 
      Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220902
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 839I73S42A (Liraglutide)
RN  - EC 2.6.1.- (Transaminases)
SB  - IM
MH  - *Anti-Obesity Agents/therapeutic use
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Liraglutide
MH  - *Non-alcoholic Fatty Liver Disease/complications/drug therapy/epidemiology
MH  - Obesity/complications/drug therapy
MH  - Platelet Aggregation Inhibitors
MH  - Transaminases
MH  - Weight Loss
PMC - PMC9478023
OTO - NOTNLM
OT  - liraglutide
OT  - lorcaserin
OT  - naltrexone/bupropion
OT  - nonalcoholic fatty liver disease
OT  - obesity
OT  - orlistat
OT  - phentermine/topiramate
OT  - semaglutide
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/20 06:00
MHDA- 2022/09/21 06:00
PMCR- 2022/01/01
CRDT- 2022/09/19 04:41
PHST- 2022/07/01 00:00 [received]
PHST- 2022/08/12 00:00 [accepted]
PHST- 2022/09/19 04:41 [entrez]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.984041 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Sep 2;13:984041. doi: 
      10.3389/fendo.2022.984041. eCollection 2022.